Baseline characteristics of all participants (n=674)
| Male sex, n (%) | 345 (51.2) |
| Age, years | 48.2 (15.8) |
| HbA1c, mmol/mol | 62.8 (13.4) |
| HbA1c, % | 7.9 (1.2) |
| Type of diabetes | |
| Type 1 DM, n (%) | 527 (78.2) |
| Type 2 DM, n (%) | 98 (14.5) |
| LADA, n (%) | 37 (5.5) |
| MODY, n (%) | 3 (0.4) |
| Other forms, n (%) | 9 (1.3) |
| Complications | |
| Microvascular complications, n (%) | 230 (34.1) |
| Neuropathy, n (%) | 88 (13.1) |
| Albuminuria, n (%) | 110 (16.3) |
| Retinopathy, n (%) | 100 (14.8) |
| Macrovascular complications, n (%) | 86 (12.8) |
| Angina pectoris, n (%) | 15 (2.2) |
| Myocardial infarction, n (%) | 22 (3.3) |
| PCI, n (%) | 30 (4.5) |
| CABG, n (%) | 23 (3.4) |
| TIA, n (%) | 17 (2.5) |
| CVA, n (%) | 14 (2.1) |
| Peripheral arterial disease, n (%) | 32 (4.7) |
| Diabetes-related hospital admissions past 12 months, yes, n (%) | 74 (11.0) |
| Diabetes-related work absenteeism past 6 months, yes, n (%) | 25 (3.7) |
| Estimated strips use per day | 2.0 (0–5.5) |
| Presence of any hypoglycemic events in past 6 months, n (%) | 622 (92.3) |
| Estimated or measured number of hypoglycemic events in past 6 months | 40.0 (15–80) |
| Therapy | |
| Insulin monotherapy, n (%) | 575 (85.6) |
| OBGLD, n (%) | 1 (0.1) |
| Insulin and OBGLD, n (%) | 96 (14.3) |
Data are presented as number (%), mean (SD) or median (25th, 75th percentile).
CABG, coronary artery bypass grafting; CVA, cerebral vascular event; DM, diabetes mellitus; LADA, latent autoimmune diabetes in adults; MODY, maturity-onset diabetes of the young; OBGLD, oral blood glucose lowering drug; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.